M1095-PSA-303: A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (PsA)

sonelokimab (M1095) - Avillion, MoonLake Immunotherap

Mar 9, 2026